ALSO NOTED: GSK files for Cervarix OK; Solvay discusses schizophrenia data;and much more...

> GlaxoSmithKline has formally submitted an application to the FDA for marketing approval of its HPV vaccine Cervarix. The application will put Glaxo about 16 months behind Gardasil, which won approval last summer, in the race for a global market worth an estimated $2 billion to $4 billion. Both vaccines have demonstrated an ability to block two strains of HPV that account for 70 percent of all cervical cancers. Report

> Solvay and Wyeth announced that they had presented positive data on their schizophrenia drug bifeprunox at an international medical conference this week. Report

> Invitrogen has partnered with Emiliem to screen the company's multi-kinase inhibitors using Invitrogen's SelectScreen platform. Release

> Galapagos NV has reached two milestones in its discovery alliance with GlaxoSmithKline in osteoarthritis, triggering payments of €3.2 million from GSK. Release

> The EMEA has restricted use of Sanofi-Aventis' antibiotic Ketek and revised the safety warning on the drug. Report

> The European Commission has approved Xeloda with chemotherapy as a first-line therapy for advanced stomach cancer. Report

And Finally... An Indonesian doctor is being treated for suspected bird flu after treating a teenage patient who had the disease. Authorities say the doctor wore a protective suit while he was treating the patient. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.